Literature DB >> 25703787

Emerging role of IL-16 in cytokine-mediated regulation of multiple sclerosis.

Dusanka S Skundric1, William W Cruikshank2, Paul C Montgomery1, Robert P Lisak3, Harley Y Tse4.   

Abstract

Cytokines are pleiotropic soluble mediators of cellular functions. Cytokines are critical in immune pathogenesis of human diseases, including autoimmune CD4(+) T cell mediated chronic inflammatory, demyelinating and neurodegenerative diseases of the central nervous system (CNS), multiple sclerosis (MS). In MS and its experimental model, experimental autoimmune encephalomyelitis (EAE), chronic persistence and/or reoccurrence of inflammation in the CNS causes chronic progressive or relapsing disease, accompanied with demyelination and damage to axons and oligodendrocytes, which ultimately leads to paralysis and disability. As opposed to other cytokines, whose effects are not limited to the CD4(+) T cell subset, IL-16 exerts its biological properties by exclusive binding and signaling through CD4 receptor. IL-16 selectively regulates migration of all CD4 expressing T cells regardless of their activation state, which is of critical importance for immune modulation and potential therapy of MS. Other major biological properties of IL-16 essential for the function of CD4(+) T cells include regulation of: T cell activation, CD25 expression, MHC class II expression, dendritic cell (DC)-T cell cooperation, B cell-T cell and T cell-T cell cooperation, inflammatory cytokine production and modulation of chemokine regulated T cell chemo-attraction. In this article we outline immune pathogenesis of the disease necessary to understand significance of cytokines and IL-16 in MS regulation. We revisit cytokine regulation with emphasis on involvement of IL-16 mechanisms, implicated in MS progression and important for development of new therapies. We emphasize the significance of similar IL-16 mechanisms for other chronic inflammatory CNS diseases.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytokines; Experimental autoimmune encephalomyelitis (EAE); Immune pathogenesis; Interleukin-16 (IL-16); Multiple sclerosis (MS)

Mesh:

Substances:

Year:  2015        PMID: 25703787     DOI: 10.1016/j.cyto.2015.01.005

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  14 in total

1.  Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.

Authors:  Barbara L Andersen; Neha Godiwala Goyal; David M Weiss; Travis D Westbrook; Kami J Maddocks; John C Byrd; Amy J Johnson
Journal:  Cancer       Date:  2018-05-14       Impact factor: 6.860

2.  HMGB1 as a potential new marker of disease activity in patients with multiple sclerosis.

Authors:  Maria Bucova; Beata Majernikova; Vladimira Durmanova; Daniela Cudrakova; Karin Gmitterova; Iveta Lisa; Eleonora Klimova; Kristina Kluckova; Milan Buc
Journal:  Neurol Sci       Date:  2019-11-14       Impact factor: 3.307

3.  Ethanol-Induced TLR4/NLRP3 Neuroinflammatory Response in Microglial Cells Promotes Leukocyte Infiltration Across the BBB.

Authors:  Silvia Alfonso-Loeches; Juan Ureña-Peralta; M José Morillo-Bargues; Ulises Gómez-Pinedo; Consuelo Guerri
Journal:  Neurochem Res       Date:  2015-11-11       Impact factor: 3.996

4.  Association of a miRNA-binding site polymorphism in IL-16 gene with disease risk and clinical characteristics of rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Somayeh Zeinalzadeh; Nahid Kheradmand; Ghazal Rasouli; Emran Esmaeilzadeh; Bahram Pakzad; Javad Behroozi; Mohsen Chamanara; Mojtaba Yousefi Zoshk; Naeim Ehtesham; Mehrdad Nasrollahzadeh Sabet
Journal:  Clin Rheumatol       Date:  2022-03-24       Impact factor: 2.980

5.  Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes.

Authors:  Nellie A Martin; Arkadiusz Nawrocki; Viktor Molnar; Maria L Elkjaer; Eva K Thygesen; Miklos Palkovits; Peter Acs; Tobias Sejbaek; Helle H Nielsen; Zoltan Hegedus; Finn Sellebjerg; Tihamer Molnar; Eudes G V Barbosa; Nicolas Alcaraz; Ferenc Gallyas; Asa F Svenningsen; Jan Baumbach; Hans Lassmann; Martin R Larsen; Zsolt Illes
Journal:  PLoS One       Date:  2018-08-16       Impact factor: 3.240

6.  An Investigation into Proteomic Constituents of Cerebrospinal Fluid in Patients with Chronic Peripheral Neuropathic Pain Medicated with Opioids- a Pilot Study.

Authors:  Jonathan Royds; Hilary Cassidy; Melissa J Conroy; Margaret R Dunne; David Matallanas; Joanne Lysaght; Connail McCrory
Journal:  J Neuroimmune Pharmacol       Date:  2020-11-20       Impact factor: 4.147

7.  Increased Levels of IL-16 in the Central Nervous System during Neuroinflammation Are Associated with Infiltrating Immune Cells and Resident Glial Cells.

Authors:  Shehla U Hridi; Mark Barbour; Chelsey Wilson; Aimee Jpm Franssen; Tanith Harte; Trevor J Bushell; Hui-Rong Jiang
Journal:  Biology (Basel)       Date:  2021-05-27

8.  Chemotactic signaling and beyond: link between interleukin-16 and axonal degeneration in multiple sclerosis.

Authors:  Dusanka S Skundric
Journal:  Neural Regen Res       Date:  2015-11       Impact factor: 5.135

9.  Association of IL-16 gene polymorphisms with the risk of developing type 2 diabetes mellitus in the Chinese Han population.

Authors:  Fangxiao Cheng; Lu Liu; Hongli Zhang; Yi Zhu; Xiaohua Li; Hong Li
Journal:  Biosci Rep       Date:  2019-08-15       Impact factor: 3.840

10.  A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis.

Authors:  Akshaya Ramesh; Ryan D Schubert; Ariele L Greenfield; Ravi Dandekar; Rita Loudermilk; Joseph J Sabatino; Matthew T Koelzer; Edwina B Tran; Kanishka Koshal; Kicheol Kim; Anne-Katrin Pröbstel; Debarko Banerji; Chu-Yueh Guo; Ari J Green; Riley M Bove; Joseph L DeRisi; Jeffrey M Gelfand; Bruce A C Cree; Scott S Zamvil; Sergio E Baranzini; Stephen L Hauser; Michael R Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.